Título
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Autor(es)
Palabras clave
Fecha de publicación
2020
Editor
Elsevier
Citación
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10. PMID: 31836199.
Resumen
[EN]Standard-of-care treatment for patients with newly diagnosed multiple myeloma includes combination
therapies for patients who are not eligible for autologous stem-cell transplantation. At the primary analysis for
progression-free survival of the phase 3 ALCYONE trial, progression-free survival was significantly longer with
daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan,
and prednisone (VMP) alone in patients with transplant-ineligible, newly diagnosed multiple myeloma. Here we
report updated efficacy and safety results from a prespecified, interim, overall survival analysis of ALCYONE with
more than 36 months of follow-up.
URI
ISSN
0140-6736
DOI
10.1016/S0140-6736(19)32956-3
Versión del editor
Aparece en las colecciones
